Current Report Filing (8-k)
January 05 2021 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 3, 2021
Yew
Bio-Pharm Group, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-54701
|
|
26-1579105
|
(State
or other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
9460
Telstar Avenue, Suite 6
El
Monte, California
|
|
91731
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (626)-401-9588
Not
Applicable
|
(Former
name or former address if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
YEWB
|
|
OTC
Markets Group
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company. [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
SAFE
HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Information
included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information may involve known and
unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group,
Inc. (herein referred to as the “Company” or “Registrant”), to be materially different from future results,
performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve
assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the
words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,”
“believe,” “intend” or “project” or the negative of these words or other variations on these
words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no
assurance that any projections or other expectations included in any forward-looking statements will come to pass. The Company’s
actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various
factors. Except as required by applicable laws, the Company undertakes no obligation to update publicly any forward-looking statements
for any reason, even if new information becomes available or other events occur in the future.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
Resignation
of Director
On
January 3, 2021, Mr. Guoshuang Tian resigned as a Director of the Company, in order to pursue other interests and businesses.
The Company thanks Mr. Tian for his service to the Company and wishes him the best in his future endeavors. There were
no adverse reasons for Mr. Tian’s resignation.
The
opening will be filled by the Board after its due diligence regarding the selection process.
Signature(s)
Pursuant
to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the Undersigned hereunto duly authorized.
|
Yew
Bio-Pharm Group, Inc.
|
|
|
Date:
January 5, 2021
|
By:
|
/s/
Zhiguo Wang
|
|
|
Zhiguo
Wang
|
|
|
President
& Chief Executive Officer
|
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Jul 2023 to Jul 2024